The Study
Effect of genetic polymorphism of OATP-C (SLCO1B1) on lipid-lowering response to HMG-CoA reductase inhibitors.
This study shows that people with a certain gene variation might not lower their cholesterol as much when taking statin medicines, but it doesn’t prove the gene is the reason. It’s like noticing a pattern, but we can’t say one thing caused the other because other factors might be involved.
Analysis score
Maximum 72 for a cohort study.
Where the score came from
Some people have different versions of a gene that can change how well their body uses cholesterol-lowering drugs.
Where does this study sit?
Systematic Reviews & Meta-analyses
Max 100Randomized Trials
Max 90Cohort Studies
Max 72Case-Control
Max 58Cross-Sectional
Max 44Case Reports & Series
Max 30Expert Opinion
Max 542 / 100
Quality score
Groups of people are followed over time to see who develops an outcome. Strong for identifying risk factors and associations, but cannot prove causation as firmly as RCTs.
Key takeaways
Summary
Based on the study abstract and findings.
- 1Yes, this means the drug works less well in some people because of their genes.
- 2People with the T gene version had their cholesterol drop by 22.3%.
- 3People with the C version had a smaller drop: only 16.5%.
Score breakdown, methodology, conflicts of interest, evidence analysis & raw study data
Publication
Journal
Drug metabolism and pharmacokinetics
Year
2004
Authors
Rieko Tachibana-Iimori, Y. Tabara, H. Kusuhara, K. Kohara, R. Kawamoto, J. Nakura, K. Tokunaga, I. Kondo, Y. Sugiyama, T. Miki
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.